Share chart Cogent Biosciences, Inc.
Extended chart
Simple chart
About
Биофармацевтическая компания Unum Therapeutics Inc. специализируется на разработке ряда новых методов лечения онкологических больных. Новая запатентованная технология компании, известная как Bolt-On Chimeric Receptor (BOXR), разработана для улучшения функциональности сконструированных Т-клеток путем обнаружения и включения трансгена «болт-на» в сконструированные Т-клетки пациента для преодоления резистентности микроокружение солидной опухоли для атаки Т-клеток.
More details| P/S | 0.9658 |
|---|---|
| EV/EBITDA | 0.3129 |
| EBITDA | -0.0309 |
| Цена ао | 11.6 |
| Сайт | http://www.cogentbio.com |
| P/BV | 0.6841 |
| Число акций ао | 0.07966 млрд |
| ISIN | US19240Q2012 |
| Выручка | 0.0225 |
| Валюта | usd |
| IPO date | 2018-03-29 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Change price per day: | +1.44% (11.09) |
|---|---|
| Change price per week: | +1.26% (11.11) |
| Change price per month: | +9.54% (10.27) |
| Change price per 3 month: | +21.62% (9.25) |
| Change price per half year: | +74.15% (6.46) |
| Change price per year: | +19.62% (9.405) |
| Change price per 3 year: | +22.55% (9.18) |
| Change price per 5 year: | +546.55% (1.74) |
| Change price per year to date: | +72.55% (6.52) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Blackrock Inc. | 6755584 | 7.07 |
| Kynam Capital Management, LP | 5854766 | 6.12 |
| Tcg Crossover Management, Llc | 5631042 | 5.89 |
| COMMODORE CAPITAL LP | 5566026 | 5.82 |
| FMR, LLC | 5302854 | 5.55 |
| Point72 Asset Management, L.P. | 5191448 | 5.43 |
| VR Adviser, LLC | 4684167 | 4.9 |
| Vanguard Group Inc | 4534655 | 4.74 |
| State Street Corporation | 4150615 | 4.34 |
| Suvretta Capital Management, LLC | 3710539 | 3.88 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares ESG Aware MSCI USA Small-Cap ETF | 0.05316 | 39.294631710362 | 1.49366 |
| iShares Morningstar Small-Cap ETF | 0.01798 | 37.681332167863 | 1.60498 |
| iShares Morningstar Small-Cap Growth ETF | 0.02305 | 41.553945249597 | 0.72598 |
| iShares Morningstar Small Cap Value ETF | 0.01318 | 40.493824576094 | 2.50476 |
| iShares Micro-Cap ETF | 0.25553 | 43.316995205115 | 1.54048 |
| iShares Russell 2000 Growth ETF | 0.06937 | 47.42032299557 | 0.6026 |
| iShares Russell 3000 ETF | 0.00184 | 37.942616648456 | 1.43482 |
| iShares Morningstar Small-Cap ETF | 0.01798 | 410.50632631881 | 1.60498 |
| iShares Morningstar Small-Cap Growth ETF | 0.02305 | 757.51743375174 | 0.72598 |
| iShares Morningstar Small-Cap Value ETF | 0.01318 | 252.86210418795 | 2.50476 |
| Principal Healthcare Innovators ETF | 0.1166 | 631.79771324797 | 0.8416 |
| Future Tech ETF | 0.1166 | 412.888593871 | 0.8416 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Andrew R. Robbins M.B.A. | President, CEO & Director | 1.06M | 1976 (48 years) |
| Mr. John L. Green C.A., CPA | CFO & Principal Accounting Officer | 763.99k | 1980 (44 years) |
| Dr. Jessica Sachs M.D. | Chief Medical Officer | 773.92k | 1975 (49 years) |
| Mr. Brad Barnett | Chief Technology Officer | N/A | |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer | 749.89k | 1975 (49 years) |
| Ms. Erin Schellhammer | Chief People Officer | N/A | |
| Mr. Evan D. Kearns J.D. | Chief Legal Officer & Corporate Secretary | N/A | 1980 (44 years) |
| Mr. Dana R. Martin Pharm.D. | Senior VP of Medical Affairs & Chief Patient Officer | N/A | |
| Brad Fell | Senior Vice President of Chemistry | N/A | |
| Ms. Christi Waarich | Senior Director of Investor Relations |
Address: United States, Cambridge, MA , 200 Cambridge Park Drive - open in Google maps, open in Yandex maps
Website: http://www.cogentbio.com
Website: http://www.cogentbio.com
